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(OCT, St Jude).
Results: 71 Patients (77 lesions, 60+/-13 years old, 57 males, 7 diabetics) underwent
coronary angiography at 12 months after BVS implantation for acute coronary syn-
dromes (42 NSTEMI, 29 STEMI). OCT was performed in 65 lesions; endothelial
function (intracoronary infusions of three different doses of acetylcholine) and
endothelium-independent vasodilation (intracoronary nitroglycerin, 200microgr) were
tested in 54 patients. Results The culprit lesion was identiﬁed in all cases with OCT.
The minimum thickness of the ﬁbrous cap covering the lesion was 0 to 550 micro-
meter (mean 232+/-139microm). Incomplete BVS expansion was evidenced in 20
cases and malapposition in 15. The minimum lumen area was 2 to 11 mm2. There
were 3 cases of in-BVS restenosis, maximal neointima thickness was 370+/-
220microm), uncovered struts were observed in 12 lesions. Vasodilation beyond the
minimum resolution of angiography was observed in 40% of the lesions, and vaso-
constriction in 30%.
Conclusions: 12 months after BVS implantation, the presence of a ﬁbrotic cap and of
phisiologic vasodilation in response to endothelium-dependent acetylcholine conﬁrm
an effective stabilization of the culprit plaque. These data provide a rationale for the
use of BVS in the setting of culprit lesions and the basis for a long-term randomized
study comparing BVS with traditional metal stents.
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Background: To date no data exist on clinical outcomes of patients with calciﬁed
lesions treated with bioresorbable vascular scaffolds (BVS).
Methods: We analyzed 8-month clinical outcome data of consecutive patients with at
least one calciﬁed lesion [deﬁned as calcium arc>60o on IVUS (performed in 78.6%
of cases) or in the absence of IVUS at least moderate lesion calciﬁcation on angi-
ography] treated with BVS between May 2012 and May 2014. Primary outcome was
major adverse cardiovascular event [MACE: deﬁned as all-cause death, myocardial
infarction (MI) and target-vessel revascularization (TVR)] rate, at median follow up
time.
Results: Out of a total of 163 patients treated with BVS, 62 (38%) had at least one
calciﬁed lesion. Mean age of the latter was 63.810.5 years and 54 (87.1%) were
male. There were 22 (35.5%) patients with diabetes, 3 (4.8%) patients with previous
CABG and 31 (50%) with previous PCI. Mean SYNTAX score was 18.899.7,
whereas left ventricular ejection fraction was 55.57.8%. Mean total stent length
per patient was 53.329.3mm. Of a total of 76 calciﬁed lesions 82.9% were AHA
type B2/C, 3.9% were in-stent restenosis, 5.3% were chronic total occlusions and
51.3% were bifurcation lesions. Average calcium arc angle was 189.8101.2o. Left
anterior descending was involved in 67.1% of lesions, circumﬂex in 19.7%, right
coronary artery in 11.8% and left main in 1.3%. Predilatation was performed in all
cases with conventional balloons whereas a scoring balloon was used in 26.3% of
cases and rotablation in 11.8%. Postdilatation was used in all but one case (98.7%),
with an average maximum pressure of 20.75.1atm. Minimal luminal area (MLA)
increased from 3.181.34 pre-procedure to 6.41.65 mm2(minimum stent area)
post BVS implantation, p< 0.001. At median follow up of 8.7 (4.9 to 13.4) months
4 (6.5%) MACE occurred. There were no deaths observed, one MI (1.6%), 3 (4.8%)
cases of TLR, 4 (6.5%) of TVR and one case (1.6%) of deﬁnite late stent
thrombosis.
Conclusions: Excellent short term results are observed in patients with calciﬁed
lesions treated with BVS. Meticulous lesion preparation is essential.
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Background: The safety and performance of the Absorb Bioresorbable Vascular
Scaffold (Absorb, Abbott Vascular, Santa Clara, CA) has been previously
demonstrated with clinical data up to 5 years (Cohort A), 3 years (Cohort B), 2
years (EXTEND). ABSORB FIRST is designed for post-approval surveillance of
Absorb BVS used in complex lesions and patients typically treated in real-world
settings.
Methods: ABSORB FIRST is a prospective, multi-center, global registry to eval-
uate the safety and effectiveness of Absorb in the real-world, all-comer population
as per Instructions for Use. This study aims to evaluate 1800 patients with de novo
lesions at approximately 90 sites in more than 20 countries worldwide. TreatmentJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Stestrategy is determined by physician and limited to lesions in vessels without prior
intervention. The key clinical endpoints include scaffold thrombosis, cardiac death,
myocardial infarction, revascularization, MACE, TLF, and TVF. All reportable
adverse events are 100% monitored and clinical events are independently
adjudicated.
Results: This is the largest report of 30-day post-PCI clinical results in Absorb-
treated patients from a single trial (ABSORB FIRST, N¼1,200). Compared to the
Cohort A, B and EXTEND these patients are at greater risks of CAD, higher rates
of dyslipidemia (65.8% %), hypertension (64.8%), diabetics (25.1%), family
history of premature CAD (37.9%), multi-vessel disease (48.4%), and prior car-
diac interventions (24.4%). There is also a high proportion of patients with Class
B2/C lesions (48.3 %), moderate/severe calciﬁed lesions (18.6%), bifurcations
(12.1%), total occluded lesions (10.4%), ostial lesions (6.2%). The mean lesion
length is 18.6  9.2 mm. The device success and procedure success rates were
98.4 % and 97.9 %, respectively. Subgroup analyses by patient and lesion com-
plexities, access site, and physician’s treatment techniques and implantation
experience with BVS will also be reported. Clinical results up to 30 days will be
discussed.
Conclusions: The interim results from this large, global registry demonstrate excellent
acute and sub-acute performance of Absorb in complex, real-world patients.TCT-614
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Background: The process of bioresorption following Absorb bioresorbable
vascular scaffold (Absorb, Abbott Vascular) placement has been investigated by op-
tical coherence tomography (OCT) and intravascular ultrasound imaging modalities;
however, the details of histomorphological changes within the strut remain poorly
characterized. We present detailed histological characterization of the strut composi-
tion in porcine coronary arteries from 6 to 48 months (mo).
Methods: A total of 32 Absorb in swine coronary arteries (29 animals) from 8 time
points (6, 12, 18, 24, 30, 36, 42, and 48 mo, 4 Absorb from each time point) were
evaluated using histologic and immunohistological stains (Figure).
Results: Struts are of stable morphology through 18 mo, being unstained and easily
identiﬁed under polarized light (Figure). Thereafter, there is rapid decline in bire-
fringence of strut sites and color changes marked by increased proteoglycan staining
by Movat and Alcian blue (blue-green, 24 mo) and increasing eosinophilia by H&E
(30 mo). These changes correspond to the absorption and inspissation of proteins
(presence of albumin). Strut sites are eventually composed of a provisional matrix that
matures from collagen Type III integration (36 mo) to eventual replacement by
smooth muscle cells and collagen Type I at 42 to 48 mo, demonstrating an increasing
integration of scaffold into the arterial tissue.
Conclusions: Detailed histological characterization of the Absorb struts provides
insight into the process of bioresorption and integration that may be correlated to
changes observed by in vivo imaging modalities such as OCT.nts - Drug-eluting: Bioresorbable Scaffolds B179
